About Insulet Corp. 
Insulet Corp.
Pharmaceuticals & Biotechnology
Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM). The Omnipod System features two discreet devices that eliminate the need for a bulky pump, tubing and separate blood glucose meter, provides for virtually pain-free automated cannula insertion, communicates wirelessly and integrates a blood glucose meter. The Omnipod System is a discreet two part design, the Omnipod device (Pod) and the PDM that eliminates the need for the external tubing required with conventional pumps. The Pod is a self-adhesive device that the patient fills with insulin and wears directly on the body.
Company Coordinates 
Company Details
100 Nagog Park , ACTON MA : 01720-3440
Registrar Details
Shareholding Snapshot
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 151 Schemes (62.59%)
Foreign Institutions
Held by 369 Foreign Institutions (25.03%)
Strategic Entities with highest holding
Highest Public shareholder
Management
Designation
Mr. timothy Scannell
Independent Chairman of the Board
Ms. Shacey Petrovic
President, Chief Executive Officer, Director
Dr. Wayne Frederick
Director
Ms. Sally Crawford
Independent Director
Dr. John Fallon
Independent Director
Dr. James Hollingshead
Independent Director
Dr. Jessica Hopfield
Independent Director
Revenue and Profits:
Net Sales:
649 Million
(Quarterly Results - Jun 2025)
Net Profit:
22 Million
Pharmaceuticals & Biotechnology
USD 24,606 Million (Mid Cap)
51.00
NA
0.00%
0.20
22.99%
16.82






